Galectin-3 als neuer Biomarker diastolischer Funktionsstörung bei Hämodialysepatienten

Gürel, Özgül Malçok; Yılmaz, Hikmet; Çelik, Tuğrul; Çakmak, Muzaffer; Namuslu, Mehmet; Bilgic, Ayse; Bavbek, Nüket; Akçay, Ali; Eryonucu, Beyhan

doi:10.1007/s00059-015-4303-6

Cited by 17 publications

(11 citation statements)

References 35 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study revealed a continual relationship after adjustment for age, LVEF, and NT-proBNP [ 28 ] and further implied that it is renal impairment (with signs of inflammation and fibrosis) that contributes to the prognostic properties of Gal-3 in HFpEF. Supplementary work by Gurel et al [ 29 ] suggested the potential use of Gal-3 in detecting HFpEF in patients undergoing hemodialysis. The present results demonstrate a significant relationship between Gal-3 levels and patient serum creatinine values across the entire HFpEF spectrum of patients.…”

Section: Discussionmentioning

confidence: 99%

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction

et al. 2018

View full text Add to dashboard Cite

BackgroundThe level of Galectin-3 (Gal-3) protein purportedly reflects an ongoing cardiac fibrotic process and has been associated with ventricular remodeling, which is instrumental in the development of heart failure with preserved ejection fraction (HFpEF) syndrome. The aim of this study was to investigate the potential use of Gal-3 in improved characterization of the grades of diastolic dysfunction as defined by echocardiography.MethodsSeventy HFpEF patients undergoing routine echocardiography were prospectively enrolled in the present monocentric study. Blood samples for measurements of Gal-3 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) were collected within 24 hours pre- or post-echocardiographic examination. The classification of patients into subgroups based on diastolic dysfunction grade permitted detailed statistical analyses of the derived data.ResultsThe Gal-3 serum levels of all patients corresponded to echocardiographic indices, suggesting HFpEF (E/A, P=0.03 and E/E', P=0.02). Gal-3 was also associated with progressive diastolic dysfunction, and increased levels corresponded to the course of disease (P=0.012). Detailed analyses of ROC curves suggested that Gal-3 levels could discriminate patients with grade III diastolic dysfunction (area under the curve [AUC]=0.770, P=0.005).ConclusionsGal-3 demonstrates remarkable effectiveness in the diagnosis of patients suffering from severe grade diastolic dysfunction. Increasing levels of Gal-3 possibly reflect the progressive course of HFpEF, as classified by the echocardiographic grades of diastolic dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In patients undergoing maintenance hemodialysis (HD), serum galectin-3 levels were correlated with early velocities/early diastolic mitral annular velocities (E'), left atrial volume index, and E'. Further analysis demonstrated that galectin-3 may be used in the diagnosis of LV diastolic function with a sensitivity and specificity of 67.6 and 84.6%, respectively ( 108 ). Serum galectin-3 levels were also revealed to be associated with LV hypertrophy independent of left ventricle geometry in patients with HD, as well as in the general population ( 109 ).…”

Section: Galectin-3 and Renal Diseasementioning

confidence: 99%

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

et al. 2017

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, which are β-galactoside-binding lectins with ≥1 evolutionary conserved carbohydrate-recognition domain. It binds proteins in a carbohydrate-dependent and -independent manner. Galectin-3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin-3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin-3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin-3 in associated diseases.

show abstract

“…Wu et al [25] reported correlations between plasma galectin-3 and E/E' in advanced HFpEF. Gurel et al [26] demonstrated that galectin-3 was an independent predictor of DD in patients with end-stage renal failure undergoing dialyses. Another study compared serum levels of galectin-3 in patients with HFrEF and HFpEF and demonstrated that it was higher in patients with HFrEF and correlated with E/E' ratio [27].…”

Section: Kinetics Of Tgf Ctgf and Galectin-3 In Patients With Varioumentioning

confidence: 99%

Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle

et al. 2020

View full text Add to dashboard Cite

Background: Fibrosis of the extracellular matrix (ECM) in dilated cardiomyopathy (DCM) is common and compromises both systolic and diastolic function. The aim of this study was to investigate the kinetics of ECM fibrosis markers over a 12 month follow-up in patients with DCM based on the severity of diastolic dysfunction (DD). Methods: Seventy consecutive DCM patients (48 ± 12.1 years, ejection fraction 24.4 ± 7.4%) were included in the study. The grade of DD was determined using the ASE/EACVI algorithm. Markers of ECM fibrosis were measured at baseline and at 3 and 12 month follow-ups: collagen type I and III (PICP, PINP, PIIICP, PIIINP), transforming growth factor beta-1 (TGF1-b), connective tissue growth factor (CTGF) and galectin-3 were measured. Results: Patients were divided into three groups according to DD severity: 30 patients with grade I, 18 with grade II and 22 with grade III of DD. Levels of PICP, PINP were increased over a 12-month period, while PIIINP decreased and PIIICP unchanged. Levels of TGF1-b decreased from the 3 to the 12-month points in grade I and II DD, and in grade III they remained unchanged. Levels of CTGF decreased over 12 months in grade III DD but were unchanged in grades I and II. Galectin-3 levels remained the same over all observation periods, irrespective of DD grade. Conclusions: Regardless of the DD grade, markers of collagen type I synthesis increased, markers of collagen type III decreased. Levels of TGF and CTGF had a tendency to decrease. Galectin-3 was revealed not to be a marker discriminating the severity of DD.

show abstract

Galectin-3 als neuer Biomarker diastolischer Funktionsstörung bei Hämodialysepatienten

Abstract: We suggest that gal-3 may be a promising biomarker for the detection of LVDD in HD patients.

Cited by 17 publications

References 35 publications

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle

Contact Info

Product

Resources

About